![]() ![]() “Zosurabalpin kills bacteria in a way that is different from all other approved antibiotics.” Hergenrother, a chemistry professor at the University of Illinois who was not involved in the research but wrote of the findings for Nature. “This is a very promising advance,” said Paul J. After some chemical tinkering, that compound became zosurabalpin. After testing a library of 45,000 MCPs, the researchers came across one that seemed especially lethal against A. In their search for a new weapon, the Roche and Harvard scientists turned their attention to a group of compounds called tethered macrocyclic peptides. Over the last 50 years, these pathogens have evolved defenses faster than we can produce new drugs. The rise of drug resistance is due in part to human folly - we have long over-prescribed and misused antibiotics - but it is also because bacteria are continually finding ways to evade threats. They are also astonishingly canny for unicellular organisms, with the ability to rapidly develop new defenses against antibiotics and then pass them along to other bacteria through genetic material.Īntibiotic-resistant superbugs claim the lives of more than 1 million people globally each year. Encased in both an inner and outer membrane that antibiotics struggle to cross, gram-negative bacteria are resistant to most currently available therapies. ![]() ![]() baumannii is a type of gram-negative bacteria, a vexing category of superbugs. Their findings were published Wednesday in the journal Nature.Ĭarbapenem-resistant A. The drug was developed jointly by scientists at the Swiss pharmaceutical company Roche and at Harvard University. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |